

# Laura Gragnani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/861605/publications.pdf>

Version: 2024-02-01

100  
papers

2,218  
citations

236612

25  
h-index

243296

44  
g-index

102  
all docs

102  
docs citations

102  
times ranked

2328  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis. <i>Clinical Rheumatology</i> , 2022, 41, 147-157.	1.0	4
2	Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. <i>Autoimmunity Reviews</i> , 2022, 21, 102923.	2.5	10
3	Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 441-443.	0.5	12
4	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	3.6	12
5	Reply. <i>Hepatology</i> , 2022, 76, E11-E12.	3.6	0
6	B cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma. <i>Hematological Oncology</i> , 2022, , .	0.8	4
7	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	0.9	7
8	Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases. <i>Journal of Autoimmunity</i> , 2022, 131, 102866.	3.0	10
9	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLE study (Mixed cryoglobulinemia Rituximab Biosimilar). <i>Internal and Emergency Medicine</i> , 2021, 16, 149-156.	1.0	8
10	<i>PDCD1</i> and <i>IFNL4</i> genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , 2021, 41, 133-149.	1.9	3
11	Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , 2021, 60, 4418-4427.	0.9	4
12	DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer. <i>Cancer Research</i> , 2021, 81, 2861-2873.	0.4	15
13	Pilot screening of HBV and HCV prevalence in at risk populations due to geographical origin and conditions of socio-economic distress. <i>Digestive and Liver Disease</i> , 2021, 53, S22-S23.	0.4	0
14	Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome. <i>Minerva Gastroenterology</i> , 2021, 67, 218-226.	0.3	4
15	REPLY:. <i>Hepatology</i> , 2021, 74, 2910-2910.	3.6	1
16	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). <i>Viruses</i> , 2021, 13, 1032.	1.5	19
17	Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. <i>Hepatology</i> , 2021, 74, 1164-1173.	3.6	10
18	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	0.9	12

#	ARTICLE	IF	CITATIONS
19	Role of Notch Receptors in Hematologic Malignancies. <i>Cells</i> , 2021, 10, 16.	1.8	9
20	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patientsâ€™ subgroups. <i>Journal of Autoimmunity</i> , 2021, 125, 102744.	3.0	83
21	SARS-CoV-2 was already circulating in Italy, in early December 2019. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 3342-3349.	0.5	3
22	Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment. <i>Current Medical Research and Opinion</i> , 2020, 36, 245-249.	0.9	13
23	Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia. <i>Journal of Immunological Methods</i> , 2020, 476, 112687.	0.6	9
24	The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis. <i>Viruses</i> , 2020, 12, 1364.	1.5	5
25	Genetic and B-cell clonality markers in HCV-related cryoglobulinemic vasculitis persisting after DAA therapy. <i>Digestive and Liver Disease</i> , 2020, 52, e1.	0.4	0
26	A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders. <i>Genes and Immunity</i> , 2020, 21, 131-135.	2.2	11
27	Fibrosis Assessment in Patients with HCV or HBV Chronic Infection. , 2020, , 113-121.		0
28	Extracellular vesicles derived from CHK2 mRNA as a possible predictive marker of HCC in HCV-infected patients. <i>Digestive and Liver Disease</i> , 2019, 51, e58.	0.4	0
29	THU-447-DNA damage response CHK2 activates senescence cellular program and supports oxidative metabolism to drive hepatocellular carcinoma development. <i>Journal of Hepatology</i> , 2019, 70, e355.	1.8	0
30	P.04.20 LONGITUDINAL EVALUATION OF LIVER FIBROSIS AND OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C UNDERGOING IFN-FREE ANTIVIRAL TREATMENT. <i>Digestive and Liver Disease</i> , 2019, 51, e181.	0.4	0
31	IGG subclasses, free light chains and vascular endothelial growth factor in HCV-related mixed cryoglobulinemic syndrome. <i>Clinica Chimica Acta</i> , 2019, 493, S156-S157.	0.5	0
32	THU-095-Short and long-term evaluation of liver fibrosis and outcomes in patients with chronic hepatitis C after INF-free antiviral treatment. <i>Journal of Hepatology</i> , 2019, 70, e202-e203.	1.8	0
33	Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. <i>Liver International</i> , 2019, 39, 628-632.	1.9	31
34	Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers. <i>Digestive and Liver Disease</i> , 2019, 51, e69.	0.4	0
35	The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy. <i>Scientific Reports</i> , 2019, 9, 4128.	1.6	36
36	Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. <i>Frontiers in Microbiology</i> , 2019, 10, 475.	1.5	11

#	ARTICLE	IF	CITATIONS
37	A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 4293-4302.	0.5	6
38	Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients. <i>Digestive and Liver Disease</i> , 2018, 50, 938-943.	0.4	10
39	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2018, 68, 33-41.	1.8	19
40	Editorial: interferon-free DAAs are a great boon for patients with hepatitis C and cryoglobulinaemia—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 772-773.	1.9	0
41	Non-invasive B-cell clonality markers may help in the rational approach to HCV SVR cryoglobulinemic patients with persisting manifestations. <i>Digestive and Liver Disease</i> , 2018, 50, e356.	0.4	0
42	Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 440-450.	1.9	28
43	Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. <i>Acta Biomedica</i> , 2018, 89, 321-331.	0.2	9
44	IgG cryoglobulinemia. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 6057-6062.	0.5	9
45	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	2.5	87
46	Reply. <i>Hepatology</i> , 2017, 65, 1771-1772.	3.6	10
47	Free light chains: Eclectic multipurpose biomarker. <i>Journal of Immunological Methods</i> , 2017, 451, 11-19.	0.6	33
48	IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection. <i>Digestive and Liver Disease</i> , 2017, 49, 1233-1239.	0.4	17
49	Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. <i>Oncotarget</i> , 2017, 8, 71528-71535.	0.8	11
50	Treatment of HCV-Related Mixed Cryoglobulinemia. <i>Current Drug Targets</i> , 2017, 18, 794-802.	1.0	18
51	HCV-Related Rheumatic Manifestations and Therapeutic Strategies. <i>Current Drug Targets</i> , 2017, 18, 803-810.	1.0	8
52	Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study. <i>Current Drug Targets</i> , 2017, 18, 772-785.	1.0	47
53	HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study. <i>Digestive and Liver Disease</i> , 2016, 48, e6-e7.	0.4	1
54	Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. <i>Hepatology</i> , 2016, 64, 1473-1482.	3.6	167

#	ARTICLE	IF	CITATIONS
55	Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders. <i>Digestive and Liver Disease</i> , 2016, 48, 927-933.	0.4	14
56	High SVR rates with SMV+SOF in HCV GT1 and GT4 patients with cirrhosis or advanced fibrosis: A real practice analysis from a large regional database in Tuscany, Italy. <i>Digestive and Liver Disease</i> , 2016, 48, e5.	0.4	0
57	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. <i>Oncotarget</i> , 2016, 7, 37487-37497.	0.8	16
58	Mir-17/92 expression pattern: A molecular signature of HCV-related mixed cryoglobulinemia. <i>Digestive and Liver Disease</i> , 2015, 47, e13.	0.4	0
59	O060 : MIR-17/92 expression pattern: A molecular signature of HCV-related mixed cryoglobulinemia. <i>Journal of Hepatology</i> , 2015, 62, S221.	1.8	1
60	Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment. <i>Liver International</i> , 2015, 35, 2100-2107.	1.9	17
61	MicroRNA expression in hepatitis C virus-related malignancies: A brief review. <i>World Journal of Gastroenterology</i> , 2015, 21, 8562.	1.4	14
62	Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. <i>Autoimmunity Reviews</i> , 2015, 14, 889-896.	2.5	53
63	Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 15-31.	1.3	73
64	Notch4 and MHC class II polymorphisms contribute to HCV-related benign and malignant lymphoproliferative diseases. <i>Digestive and Liver Disease</i> , 2015, 47, e14.	0.4	0
65	Assessment of free light chains in HCV positive patients with mixed cryoglobulinemia vasculitis undergoing rituximab treatment. <i>Digestive and Liver Disease</i> , 2015, 47, e27.	0.4	0
66	P0752 : NOTCH4 and MHC class II polymorphisms contribute to HCV-related benign and malignant lymphoproliferative diseases. <i>Journal of Hepatology</i> , 2015, 62, S611.	1.8	0
67	Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy. <i>Case Reports in Immunology</i> , 2015, 2015, 1-5.	0.2	28
68	Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies. <i>Hepatology International</i> , 2015, 9, 586-593.	1.9	7
69	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. <i>Hepatology</i> , 2015, 61, 1145-1153.	3.6	107
70	Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1067-1076.	1.8	6
71	Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	16
72	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2014, 46, S165-S173.	0.4	218

#	ARTICLE	IF	CITATIONS
73	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 21.	1.8	14
74	Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , 2014, 15, 500-505.	2.2	55
75	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , 2014, 46, 833-837.	0.4	57
76	149â€fHCV AND lymphoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 63.	0.9	0
77	454 microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA. <i>Journal of Hepatology</i> , 2013, 58, S185-S186.	1.8	0
78	Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26b. <i>Journal of Hepatology</i> , 2013, 59, 1362-1363.	1.8	8
79	Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>PLoS ONE</i> , 2013, 8, e62965.	1.1	42
80	Value of <scp>IL</scp>28<scp>B</scp> genotyping in patients with <scp>HCV</scp>â€related mixed cryoglobulinemia: results of a large, prospective study. <i>Journal of Viral Hepatitis</i> , 2013, 20, e107-14.	1.0	16
81	OP0186â€...Etiological therapy in HCV-related mixed cryoglobulinemia syndrome: The role of IL28B genotype as predictor of response. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 117.3-118.	0.5	0
82	Hepatitis C virus-related mixed cryoglobulinemia: Is genetics to blame?. <i>World Journal of Gastroenterology</i> , 2013, 19, 8910.	1.4	20
83	HCV and Lymphoproliferation. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	84
84	Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. <i>Journal of Translational Medicine</i> , 2012, 10, 158.	1.8	14
85	The hepatitis C virus infection as a systemic disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 201-208.	1.0	42
86	Genetic determinants in hepatitis C virusâ€associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and FcÎ³3 receptors. <i>Arthritis and Rheumatism</i> , 2011, 63, 1446-1451.	6.7	59
87	Detection of WA B cells in hepatitis C virus infection: A potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. <i>Arthritis and Rheumatism</i> , 2010, 62, 2152-2159.	6.7	37
88	701 HOST GENETIC DETERMINANTS IN HCV-RELATED MIXED CRYOGLOBULINEMIA. <i>Journal of Hepatology</i> , 2010, 52, S272-S273.	1.8	0
89	878 HCV-RELATED MIXED CRYOGLOBULINEMIA AND BAFF PROMOTER POLYMORPHISM. <i>Journal of Hepatology</i> , 2009, 50, S319-S320.	1.8	0
90	Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. <i>Blood</i> , 2008, 111, 2943-2945.	0.6	24

#	ARTICLE	IF	CITATIONS
91	Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?. <i>Blood</i> , 2008, 112, 4353-4354.	0.6	25
92	Hepatitis C virus lymphotropism: lessons from a decade of studies. <i>Digestive and Liver Disease</i> , 2007, 39, S38-S45.	0.4	75
93	Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. <i>Digestive and Liver Disease</i> , 2007, 39, S76-S82.	0.4	10
94	Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2007, 14, 22-28.	1.0	9
95	Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. <i>Haematologica</i> , 2004, 89, 873-4.	1.7	17
96	Developmentally regulated expression of the mouse homologues of the potassium channel encoding genes m-erg1, m-erg2 and m-erg3. <i>Gene Expression Patterns</i> , 2003, 3, 767-776.	0.3	29
97	HCV infection, malignancy, and liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1032-1033.	0.3	3
98	Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. <i>Blood</i> , 2003, 102, 1196-1201.	0.6	99
99	BCL-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment. <i>Journal of Hepatology</i> , 2002, 36, 17.	1.8	0
100	HERG K <sup>+</sup> Channels Activation during $\alpha$ 2 $\beta$ 1 Integrin-mediated Adhesion to Fibronectin Induces an Up-regulation of $\alpha$ 5 $\beta$ 3 Integrin in the Preosteoclastic Leukemia Cell Line FLG 29.1. <i>Journal of Biological Chemistry</i> , 2001, 276, 4923-4931.	1.6	83